Key facts
- This page summarizes Pamela Vig's Form 4 filing for Mirum Pharmaceuticals, Inc. (MIRM).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 25 Jan 2024, 19:10.
Pamela Vig - 23 Jan 2024 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)
- Reporting relationship
- CHIEF SCIENTIFIC OFFICER
- Issuer ticker
- MIRM
- Reported as of
- 23 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 25 Jan 2024, 19:10:25 UTC
- Prior SEC filing
- 09 Jan 2024
- Next SEC filing
- 05 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Judit Ryvkin, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Pamela Vig filed Form 4 for Mirum Pharmaceuticals, Inc. (MIRM) on 25 Jan 2024.
Change
- Previous filing in this sequence was filed on 09 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MIRM
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +32,000
- Change %
- Price
- $0.000000
- Shares after
- 32,000
- Date
- 23 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 32,000
- Exercise price
- $26.49
- Footnotes
- F1
MIRM
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +8,000
- Change %
- Price
- $0.000000
- Shares after
- 8,000
- Date
- 23 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,000
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
1/4th of the shares vest one year after January 23, 2024 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Footnote F3
1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.